journal article·2017-09

Characterization of Tunisian clay suitable for pharmaceutical and cosmetic applications

S. Gamoudi, E. Srasra

Publisher page

Abstract

Abstract The aim of this study is to assess the suitability of purified Tunisian clay for its possible pharmaceutical and cosmetic uses. Mineralogical, chemical and physicochemical characterization was performed with the aid of tools like X-ray diffraction (XRD), Chemical composition, DTA/TGA analysis, Cation exchange capacity (CEC), particle size distribution by laser dispersion (PSD), surface area (BET method), Point of zero charge (PZC) and surface charge density σ H . Pharmacopoeia tests were also carried: Swelling capacity, sedimentation volume and pH measurement. For microbiological tests, the absence of Salmonella species, Escherichia coli , Staphylococcus aureus and Pseudomonas aeruginosa was tested. The X-ray diffraction data revealed that the Tunisian sample is an interstratified illite-smectite. The percentage of smectitic fraction is estimated to be 78%. The chemical, textural and porosimetric results show important values suggesting that this mineral clay can function in creams, powders and emulsions. In view of the fundamentals of major pharmacopoeias for use of bentonite in pharmacy and considering the swelling capacity and sedimentation volume values, and microbiological results we could designate a pharmaceutical acceptable denomination for Tunisian purified clay.
Source: openaire · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Therapeutic Uses of Natural Elements · Clay minerals and soil interactions

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (30)

Show source-provided references
1. Suitability of a Miocene bentonite from North Western Desert of Egypt for pharmaceutical use10.1016/j.clay.2011.02.012 ↗
2. CEC of clays: measurement by adsorption of a copper ethylenediamine complex10.1016/S0169-1317(97)00012-4 ↗
3. Clay and non-clay minerals in the pharmaceutical industry. Part I. Excipients and medical applications10.1016/j.clay.2009.07.017 ↗
4. Clay and non-clay minerals in the pharmaceutical and cosmetic industries Part II. Active ingredients10.1016/j.clay.2009.10.016 ↗
5. Clays and human health
6. Tramadol hydrochloride/montmorillonite composite: preparation and controlled drug release10.1016/j.clay.2010.04.011 ↗
7. Sensitivity of the acid–base properties of clays to the methods of preparation and measurement 2. Evidence from continuous potentiometric titrations10.1016/j.jcis.2005.03.057 ↗
8. European Pharmacopoeia · 2005 · 1068
9. Physical and chemical characterization and method for the decontamination of clays for application in cosmetics10.1016/j.clay.2016.02.022 ↗
10. Mechanism of kaolinite dissolution at room temperature and pressure: Part I. Surface speciation10.1016/S0016-7037(97)00366-9 ↗
11. Montmorillonite as a drug delivery system: intercalation and in vitro release of timolol maleate10.1016/j.ijpharm.2009.03.004 ↗
12. Some properties of thermal muds of some spas in Turkey10.1016/j.clay.2010.02.005 ↗
13. Acid–Base chemistry of montmorillonitic and beidellitic-montmorillonitic smectite10.1134/S102319350702005X ↗
14. A study of purified montmorillonite intercalated with 5-fluorouracil as drug carrier10.1016/S0142-9612(01)00325-8 ↗
15. Characterization of Iranian bentonites to be used as pharmaceutical materials10.1016/j.clay.2015.03.013 ↗
16. Differences between structural, textural and rheological properties of two Cameroonian mineral clays used as cosmetic mask
17. Estimation of the point of zero charge of simple oxides by mass titration10.1016/0021-9797(89)90086-6 ↗
18. van Olphen · 1963
19. Controlled release of donepezil intercalated in smectite clays10.1016/j.ijpharm.2008.04.012 ↗
20. Flow and ductility of smectite clay for skin treatment
21. The nature of interlayering in mixed-layer illite-montmorillonites10.1346/CCMN.1970.0180104 ↗
22. Physicochemical study of the interaction of montmorillonite with hydralazine hydrochloride, a cardiovascular drug10.1016/0169-1317(88)90005-1 ↗
23. Surface charge properties of kaolinite10.1346/CCMN.1997.0450110 ↗
24. Characterization of Pakistani purified bentonite suitable for possible pharmaceutical application10.1016/j.clay.2013.08.007 ↗
25. Engineering properties of kaolinitic clay with potential use in drugs and cosmetics
26. Precise identification of illite/smectite interstratifications by X-ray powder diffraction10.1346/CCMN.1980.0280601 ↗
27. Element mobility in clays for healing use10.1016/j.clay.2006.05.011 ↗
28. Healing clays: mineralogical and geochemical constraints on the preparation of clay–water suspension (“argillic water”)10.1016/j.clay.2006.05.004 ↗
29. US Pharmacopoeia 30-NF 25 · 2007 · 83
30. Pharmaceutical applications of some Spanish clays (sepiolite, palygorskite, bentonite): some preformulation studies10.1016/S0169-1317(98)00050-7 ↗